Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Heptaminol→

Heptaminol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
372-66-7
Molecular formula
C8H19NO
Molecular weight
145.25 g/mol
Drug class
Amino alcohol sympathomimeticvasopressor and cardiotonic agent
Mechanism of action
The precise mechanism is not fully established. Proposed actions include modulation of catecholamine release and calcium handling, producing cardiovascular stimulation and peripheral vascular effects.
Indications / reported uses
  • Historically and in some jurisdictions used for symptomatic treatment of orthostatic hypotension and selected circulatory disorders; the exact current product indication and availability are jurisdiction-specific.

Sources: https://meshb.nlm.nih.gov/record/ui?name=Heptaminol · https://pubchem.ncbi.nlm.nih.gov/compound/Heptaminol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Heptaminol Environmental Risk Assessment (ERA) (the Heptaminol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.